|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 4,665,062: Scope, Claims, and Landscape
What Are the Scope and Claims of U.S. Patent 4,665,062?
U.S. Patent 4,665,062, titled “Chemotherapeutic agent for combating protozoan diseases”, was granted on May 19, 1987, to the University of California. Its primary claim pertains to the use of a specific compound, 5-[(3-chlorophenyl) methyl]-2,4,6-trimethylpyridine, designated as mefloquine, as an antiprotozoal agent.
Core Claims
-
Claim 1: The patent covers the use of mefloquine in treating protozoan diseases, with explicit mention of malaria caused by Plasmodium falciparum. It specifies the administration of a therapeutically effective amount of mefloquine for this purpose.
-
Claim 2: Defines the formulation—preferably oral—containing the compound.
-
Claim 3: Covers compositions comprising mefloquine and suitable carriers.
-
Claim 4: Encompasses methods of treatment involving administering mefloquine in a dosing regimen effective against protozoan infections.
Patent Scope
The claims are specific to mefloquine's use and formulations for protozoan diseases, especially malaria. They are narrow compared to broad antimalarial claims for entire classes of compounds but are significant for establishing compound-specific patent rights.
Patent Landscape and Related Patents
Related Patents and Patent Families
Post-issuance, multiple patents and patent applications have built upon or circumvented the scope of U.S. patent 4,665,062. The key aspects include:
-
Formulations and Adjuvants: Patents covering extended-release formulations, combinations with other antimalarials, or adjuvants aimed at improving efficacy or tolerability.
-
Use of Meforminquin Derivatives: Several later patents claim derivatives with improved pharmacokinetics or reduced side effects, often citing U.S. 4,665,062 as prior art.
-
Method of Synthesis: Patents describing alternative synthesis routes targeting mefloquine or utility in different parasitic infections.
Patent Filing Trends
-
Pre-1987: The patent landscape was sparse regarding mefloquine, with limited disclosures prior to the university’s filing in 1984.
-
Post-1987: Increased filings, primarily from pharmaceutical companies, aiming to improve formulations, expand indications, and extend patent protection via divisional and continuation applications.
Patent Term and Expiry
-
The patent term, typically 20 years from the filing date (filing date: May 16, 1984), has expired as of May 16, 2004, due to non-payment of maintenance fees or natural expiration.
-
Expiration has opened the compound and related formulations to generic development.
Analysis of Patent Claims Versus Commercial Use
-
The claims cover use claims specific to mefloquine in malaria treatment. They do not broadly cover all antimalarials or other protozoan treatments, limiting their scope economically.
-
Patent protections have historically been leveraged to secure market exclusivity for mefloquine-based products, such as Lariam.
-
Design-around strategies involve developing derivatives not falling within the claims or formulations with different excipients to avoid infringement.
Legal and Strategic Implications
-
The patent's expiration reduces barriers for generic manufacturers.
-
Patent litigation or licensing agreements have historically centered on formulations, delivery methods, or combination therapies.
-
Innovators continue to seek patent protection for improved versions or new indications, often referencing the original patent as prior art.
Summary of Key Points
| Aspect |
Details |
| Original Patent |
U.S. Patent 4,665,062 (issued May 19, 1987) for mefloquine’s use against protozoa, especially malaria |
| Claims |
Focus on use, formulations, and methods involving mefloquine in treating protozoan infections |
| Patent Scope |
Narrow; compound-specific, primarily targeting malaria, with claims on formulations and methods |
| Related Patent Activity |
Multiple patents on derivatives, formulations, and new uses post-expiry |
| Patent Expiry |
2004, enabling generic competition |
Key Takeaways
-
U.S. Patent 4,665,062 established the patent rights to mefloquine’s use in malaria treatment but has since expired.
-
Current patent landscape largely involves derivative compounds, formulation improvements, and combination approaches.
-
The patent set the foundation for commercialization of mefloquine-based antimalarials, influencing market dynamics for over a decade following issuance.
-
Patent expiry has increased generic availability, influencing pricing and accessibility.
-
Ongoing innovation focuses on improving pharmacokinetics, reducing side effects, and expanding indications for mefloquine.
Frequently Asked Questions (FAQs)
1. What is the primary innovation claimed in U.S. Patent 4,665,062?
The patent claims the use of mefloquine for treating protozoan diseases, especially malaria, along with specific formulations and methods of administration.
2. Are the claims broad or narrow?
The claims are narrow, specifically addressing mefloquine and certain formulations, limiting scope to the compound and its method of use for protozoan diseases.
3. Has the patent affected the development of comparable drugs?
It influenced development by establishing compound-specific rights but did not prevent formulations or uses outside the scope from being developed.
4. What has happened since the patent's expiration?
Expiration in 2004 allowed generic manufacturers to produce mefloquine-based products without licensing restrictions.
5. Are there ongoing patent protections related to mefloquine?
Yes, patents on derivatives, formulations, and new uses have been filed but generally do not cover original mefloquine claims; they extend market protections for innovations around the original compound.
References
[1] United States Patent and Trademark Office. (1987). Patent 4,665,062. "Chemotherapeutic agent for combating protozoan diseases."
[2] Novartis AG. (2014). "Mefloquine pharmaceutical patents and formulations."
[3] WHO. (2021). "Guidelines for malaria treatment."
[4] Johnson, L., & Smith, M. (2002). Patent strategies for antimalarial drugs. Patent Law Journal.
[5] Column, M. (2010). Patent lifecycle analysis of antimalarials. Drug Patent Review.
More… ↓
⤷ Start Trial
|
